Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Jan 19 2012

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application (CTA). This allows Rexahn to initiate an exploratory first-in-human Phase I clinical trial of RX-3117.

RX-3117 is a small molecule antimetabolite for the treatment of solid tumors.

"Preclinical studies demonstrate RX-3117 to have exciting anti-cancer properties, and we look forward to moving this compound into clinical development," said Rick Soni, President and COO of Rexahn. "We will continue to develop RX-3117, which has potential therapeutic applications in a broad range of cancers, including colon, lung and pancreatic cancer."

Source: Rexahn Pharmaceuticals, Inc.